Clarify Pharma has acquired shares to the value of £250,000 in each of Atai Life Sciences and Compass Pathways as part of its investment strategy.
Clearmind Medicine will be embarking on a first-in-human clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).
Canadian pharmaceutical development company Algernon Pharmaceuticals has commenced screening subjects for its Phase 1 clinical study of an intravenous formulation of DMT – AP-188 – in...
A team at the Allen Institute for Brain Science, a division of the Allen Institute, has sent brain samples on a “trip” to gain insights into...
Small Pharma has received approval to carry out a first-in-human Phase 1 trial with its injectable deuterated DMT candidate – SPL028 – from the UK Medicines...
Verywell Mind has carried out a survey, revealing that one in three Americans who are currently in therapy are willing to try psychedelics to help with...
Daniel Donato and his band are releasing limited VIP NFT tickets for their stacked US tour, with funds going toward vital psychedelic research at MAPS.
The University of Guelph (UoG) has announced that it is one of the first universities to be granted a licence by Health Canada to cultivate psychedelic...
Numinus Wellness is developing an innovative method of delivery for psilocybin in clinical trials and research.
The ‘Microdosing and Meditation Study’ is aiming to observe how meditation skills evolve over three months of regular meditation practice and whether, how, and for whom...